Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...

AstraZeneca’s Imfinzi is under regulatory review in China, Japan and other countries. Credit: © AstraZeneca 2025. AstraZeneca’s Imfinzi (durvalumab) plus ...

Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic rhinosinusitis with nasal polyps (CRSwNP). Tezspire showed numerically ...

Goldman Sachs analysts added AstraZeneca (AZN) to the firm’s European Conviction List as part of its monthly update. With 28 Phase-3 readouts across multiple therapeutic areas expected in 2025 ...

Tezspire targets the airway epithelium, the primary source of inflammation. Credit: Emily Frost / Shutterstock. Amgen and AstraZeneca have reported complete outcomes from the registrational Phase III ...

About the vaccine, how it works, how it is given, ingredients, allergies, possible side effects, safety monitoring ...

In a heated competition among BTK inhibitor treatments for blood cancer, BeiGene’s third-to-market Brukinsa has for the first time surpassed AstraZeneca’s Calquence in quarterly sales.

Another example is the Covid-19 collaboration between U.K.’s AstraZeneca and Serum Institute of India. “Our vaccine, developed with the University of Oxford, was manufactured by Serum Institute of ...

As­traZeneca wasn’t ex­pect­ed to have da­ta from the Phase 3 tri­al of its oral SERD un­til the sec­ond half of this year so the pos­i­tive … ...

AstraZeneca said its breast cancer drug candidate showed positive results in a late stage trial, with improved progression-free survival in patients. The British pharma giant said Wednesday that ...

AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim analysis. The trial hit on progression-free survival (PFS), its ...